ENDRA Life Sciences Inc. has announced encouraging preliminary results from a single-site clinical feasibility study evaluating its improved TAEUS Liver device for quantifying liver fat fraction, a key biomarker in steatotic liver disease (SLD), including MASLD and MASH. According to the company, the TAEUS Liver device demonstrated strong agreement with the current imaging gold standard, MRI-PDFF, across the full spectrum of steatotic liver disease and patient BMI. These results aim to validate the improved performance of the device and inform the design and statistical plan for a pivotal study in consultation with the U.S. Food and Drug Administration (FDA). A second feasibility study is currently underway in London, Ontario, Canada, with completion expected in the coming months. Results from these studies will be discussed with the FDA in pre-submission meetings prior to initiating the pivotal study and are also expected to be submitted for publication in a peer-reviewed medical journal.